- Home
- KZIA
as 06-27-2025 11:32am EST
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | NEW SOUTH WALES 2113 |
| Market Cap: | 5.1M | IPO Year: | 1999 |
| Target Price: | $57.50 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -24.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.86 - $79.00 | Next Earning Date: | 07-07-2025 |
| Revenue: | $1,549,158 | Revenue Growth: | 248983.08% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kazia Therapeutics Limited News
KZIA Breaking Stock News: Dive into KZIA Ticker-Specific Updates for Smart Investing
Simply Wall St.
16 days ago
Kazia Therapeutics First Half 2025 Earnings: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)
MT Newswires
17 days ago
Top Midday Gainers
MT Newswires
17 days ago
Kazia Therapeutics Says Preclinical Data Show Paxalisib's Potential in Reducing Breast Cancer Symptoms; Shares Jump
PR Newswire
18 days ago
Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)
MT Newswires
23 days ago
Kazia Therapeutics Doses First Patient in Phase 1 Trial of Paxalisib for Advanced Breast Cancer
PR Newswire
24 days ago
Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
PR Newswire
a month ago
Kazia Therapeutics Highlights Recent Progress and Provides Business Update
PR Newswire
3 months ago
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
Compare KZIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KZIA Kazia Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.